Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Heptares Therapeutics Ltd.-Product Pipeline Review-2015

Heptares Therapeutics Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Heptares Therapeutics Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Heptares Therapeutics Ltd.-Product Pipeline Review-2015', provides an overview of the Heptares Therapeutics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Heptares Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Heptares Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Heptares Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Heptares Therapeutics Ltd.'s pipeline products

Reasons To Buy

Evaluate Heptares Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Heptares Therapeutics Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heptares Therapeutics Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Heptares Therapeutics Ltd. Snapshot 6

Heptares Therapeutics Ltd. Overview 6

Key Information 6

Key Facts 6

Heptares Therapeutics Ltd.-Research and Development Overview 7

Key Therapeutic Areas 7

Heptares Therapeutics Ltd.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Heptares Therapeutics Ltd.-Pipeline Products Glance 16

Heptares Therapeutics Ltd.-Clinical Stage Pipeline Products 16

Phase I Products/Combination Treatment Modalities 16

Heptares Therapeutics Ltd.-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Heptares Therapeutics Ltd.-Drug Profiles 19

HTL-9936 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Drug to Agonize Muscarinic M4 Receptors for Psychosis 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

HTL-14242 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule to Agonize GPR-39 for Type 2 Diabetes 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecule to Antagonize CGRP for Migraine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody to Target GPCR for Pain, Metabolic Disorders and Inflammation 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule to Antagonize Orexin 1/2 for Insomnia 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule to Target Chemokine (C-X-C Motif) Receptor 4 for Cancer and HIV 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecule to Target GPCR for CNS Disorders 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecule to Target mGluR2 for Schizophrenia 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Target GPCR 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules to Target GPCRs for Pain, Metabolic Disorders and Inflammation 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Heptares Therapeutics Ltd.-Pipeline Analysis 35

Heptares Therapeutics Ltd.-Pipeline Products by Target 35

Heptares Therapeutics Ltd.-Pipeline Products by Route of Administration 36

Heptares Therapeutics Ltd.-Pipeline Products by Molecule Type 37

Heptares Therapeutics Ltd.-Pipeline Products by Mechanism of Action 38

Heptares Therapeutics Ltd.-Recent Pipeline Updates 39

Heptares Therapeutics Ltd.-Locations And Subsidiaries 42

Head Office 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

Heptares Therapeutics Ltd., Key Information 6

Heptares Therapeutics Ltd., Key Facts 6

Heptares Therapeutics Ltd.-Pipeline by Indication, 2015 9

Heptares Therapeutics Ltd.-Pipeline by Stage of Development, 2015 10

Heptares Therapeutics Ltd.-Monotherapy Products in Pipeline, 2015 11

Heptares Therapeutics Ltd.-Partnered Products in Pipeline, 2015 12

Heptares Therapeutics Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 13

Heptares Therapeutics Ltd.-Out-Licensed Products in Pipeline, 2015 14

Heptares Therapeutics Ltd.-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

Heptares Therapeutics Ltd.-Phase I, 2015 16

Heptares Therapeutics Ltd.-Preclinical, 2015 17

Heptares Therapeutics Ltd.-Discovery, 2015 18

Heptares Therapeutics Ltd.-Pipeline by Target, 2015 35

Heptares Therapeutics Ltd.-Pipeline by Route of Administration, 2015 36

Heptares Therapeutics Ltd.-Pipeline by Molecule Type, 2015 37

Heptares Therapeutics Ltd.-Pipeline Products by Mechanism of Action, 2015 38

Heptares Therapeutics Ltd.-Recent Pipeline Updates, 2015 39

List of Figures

Heptares Therapeutics Ltd.-Pipeline by Top 10 Indication, 2015 8

Heptares Therapeutics Ltd.-Pipeline by Stage of Development, 2015 10

Heptares Therapeutics Ltd.-Monotherapy Products in Pipeline, 2015 11

Heptares Therapeutics Ltd.-Out-Licensed Products in Pipeline, 2015 14

Heptares Therapeutics Ltd.-Pipeline by Top 10 Target, 2015 35

Heptares Therapeutics Ltd.-Pipeline by Top 10 Route of Administration, 2015 36

Heptares Therapeutics Ltd.-Pipeline by Top 10 Molecule Type, 2015 37

Heptares Therapeutics Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Heptares Therapeutics Ltd.; Heptares Therapeutics Ltd. - Key Therapeutics; Heptares Therapeutics Ltd. - Pipeline Overview and Promising Molecules; Heptares Therapeutics Ltd. - News; Heptares Therapeutics Ltd. - Latest Updates; Heptares Therapeutics Ltd. - Pipeline; Heptares Therapeutics Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com